+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Hepatitis B Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 372 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6106288
The global market for Hepatitis B Treatment was estimated at US$4.7 Billion in 2024 and is projected to reach US$5.4 Billion by 2030, growing at a CAGR of 2.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Hepatitis B Treatment market.

Global Hepatitis B Treatment Market - Key Trends & Drivers Summarized

Is the Treatment of Hepatitis B Entering a New Era of Functional Cure and Long-Term Suppression?

The treatment of Hepatitis B is undergoing a pivotal transformation, driven by advancing scientific research, improved therapeutic options, and a deeper understanding of the virus`s complex life cycle. Traditionally managed through lifelong antiviral therapy, Hepatitis B treatment has focused on suppressing viral replication to reduce the risk of liver cirrhosis, hepatocellular carcinoma (HCC), and liver failure. First-line therapies such as nucleos(t)ide analogues-including entecavir, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)-have proven effective in achieving sustained viral suppression, but fall short of offering a complete cure. However, a new wave of research is aiming for what experts call a “functional cure,” defined by the loss of hepatitis B surface antigen (HBsAg) and undetectable HBV DNA without continued treatment. Novel therapeutic candidates in clinical trials-such as capsid assembly modulators, siRNA inhibitors, and immune checkpoint modulators-are targeting different phases of the HBV life cycle and the host's immune response to push the boundaries of treatment beyond suppression. Immunotherapeutic strategies including therapeutic vaccines and T-cell activators are also gaining traction, aiming to reawaken the body's immune response against persistent viral reservoirs. Combination therapies involving antivirals plus immune modulators are being evaluated as a path forward toward sustained off-treatment control. As these investigational therapies progress through clinical trials, the treatment paradigm is shifting from lifelong management to time-limited regimens aimed at achieving functional cure, which would represent a landmark change in the global approach to chronic Hepatitis B.

Is Public Health Infrastructure and Screening Enhancing Treatment Accessibility and Uptake?

As awareness around Hepatitis B grows, improvements in public health infrastructure and global screening efforts are significantly influencing treatment accessibility and uptake. One of the biggest barriers historically has been the lack of diagnosis-most people with chronic HBV remain unaware of their status until complications like liver disease arise. In response, countries are scaling up national screening programs, integrating HBV testing into routine prenatal care, blood donor screening, and general health checkups. These measures are enabling earlier diagnosis, which is crucial since early-stage patients respond more favorably to antiviral therapy. Furthermore, decentralized healthcare models and community-based outreach are being deployed in high-burden regions-especially in Asia and sub-Saharan Africa-to improve access to treatment for underserved populations. Many nations are also revising their treatment guidelines in line with WHO recommendations, reducing the barriers to initiating therapy and expanding eligibility criteria for antiviral treatment. Additionally, integration of HBV management into broader health services such as HIV/AIDS, tuberculosis, and maternal health programs is streamlining care delivery and improving patient outcomes. Global donors and organizations like Gavi, the Global Fund, and UNITAID are supporting low- and middle-income countries by subsidizing medication costs and building lab infrastructure. Meanwhile, digital health platforms and telemedicine services are increasing outreach in remote and rural areas, enabling virtual consultations, remote monitoring, and digital prescription management. Together, these efforts are improving HBV treatment cascade-from diagnosis to retention in care-by making therapy more accessible, affordable, and aligned with the unique needs of diverse patient populations around the world.

How Are Evolving Patient Demographics and Comorbidities Reshaping Treatment Strategies?

Shifting patient demographics, along with an increase in comorbidities such as HIV, hepatitis D, diabetes, and non-alcoholic fatty liver disease (NAFLD), are adding layers of complexity to Hepatitis B treatment strategies. The rise in chronic conditions among aging populations is prompting clinicians to take a more holistic approach when initiating HBV therapy, ensuring that drug choices do not exacerbate renal or bone-related complications. This is especially relevant for older adults or those with underlying kidney disease, where tenofovir alafenamide (TAF) is often preferred over TDF due to its improved safety profile. Co-infection with HIV presents another clinical challenge, as treatment regimens must be harmonized to avoid drug-drug interactions and ensure suppression of both viruses. For patients with hepatitis D virus (HDV) co-infection-a group at higher risk of rapid disease progression-specialized antiviral strategies, including the use of novel entry inhibitors like bulevirtide, are being explored to manage dual infections effectively. In parallel, the global rise of metabolic syndromes and obesity-related liver disorders is influencing treatment timing and monitoring protocols, as liver disease progression in HBV patients is no longer driven solely by viral replication. New algorithms that integrate fibrosis scores, liver enzyme trends, and metabolic indicators are helping providers stratify risk and personalize treatment plans. Furthermore, patient adherence and quality of life considerations are becoming central to therapy design, prompting the development of once-daily oral regimens and the investigation of long-acting injectable formulations. The diversification of HBV patient profiles is thus redefining what personalized medicine looks like in the context of chronic hepatitis care, necessitating more nuanced and patient-centric treatment pathways.

What Market and Policy Drivers Are Accelerating Growth in the Hepatitis B Treatment Segment?

The growth in the Hepatitis B treatment market is driven by several interconnected forces tied to epidemiological trends, pharmaceutical innovation, health policy evolution, and patient behavior. Globally, over 250 million people live with chronic HBV, and the majority reside in low- and middle-income countries-regions now actively scaling up treatment access as part of WHO's hepatitis elimination agenda. The expansion of treatment guidelines to include patients with earlier-stage liver disease and less advanced fibrosis is widening the eligible treatment population, increasing demand for antiviral therapies. Pharmaceutical innovation continues to drive market momentum, with several next-generation therapies under development aiming to deliver functional cure, improve adherence, or reduce long-term toxicity. Simultaneously, increasing generic drug availability is making first-line antivirals more affordable, especially in high-burden countries, leading to higher patient volumes and expanded public health initiatives. Governments and health agencies are launching hepatitis B elimination plans that include budget allocations for treatment subsidies, centralized procurement strategies, and inclusion of antivirals in essential drug lists-steps that are all contributing to market expansion. Patient behavior is also shifting, with more individuals seeking testing and early intervention due to rising health awareness, digital engagement, and destigmatization of the disease. Meanwhile, partnerships between pharmaceutical companies, NGOs, and health ministries are helping to establish regional treatment hubs and supply chain networks to improve last-mile delivery. The adoption of digital health technologies-such as mobile-based adherence tools, remote monitoring platforms, and AI-powered clinical decision support systems-is enhancing patient retention and care quality. These combined factors are propelling the Hepatitis B treatment market forward, with strong long-term growth anticipated as the world moves closer to eradicating one of the most prevalent infectious diseases.

Scope Of Study:

The report analyzes the Hepatitis B Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Type (Acute Type, Chronic Type); Treatment (Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment, Surgery Treatment); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Acute Type segment, which is expected to reach US$3.5 Billion by 2030 with a CAGR of a 1.7%. The Chronic Type segment is also set to grow at 3.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.3 Billion in 2024, and China, forecasted to grow at an impressive 4.4% CAGR to reach $1.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Hepatitis B Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hepatitis B Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Hepatitis B Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie Inc., Alnylam Pharmaceuticals, Altimmune Inc., Antios Therapeutics, Arbutus Biopharma Corporation and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 39 companies featured in this Hepatitis B Treatment market report include:

  • AbbVie Inc.
  • Alnylam Pharmaceuticals
  • Altimmune Inc.
  • Antios Therapeutics
  • Arbutus Biopharma Corporation
  • Assembly Biosciences
  • Bristol-Myers Squibb
  • Dicerna Pharmaceuticals
  • Enanta Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • LG Chem
  • MYR Pharmaceuticals GmbH
  • Replicor Inc.
  • Roche Holding AG
  • Sanofi
  • VBI Vaccines Inc.
  • Vir Biotechnology, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Hepatitis B Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • High Global Disease Burden Throws the Spotlight on Expanding Access to Hepatitis B Treatment
  • Increased Government and WHO-Led Elimination Goals Propel Growth in Treatment Uptake
  • Advancements in Antiviral Therapies Strengthen Business Case for Long-Term Viral Suppression
  • Rising Screening and Diagnosis Rates Expand the Addressable Market for Hepatitis B Treatment
  • Development of Finite-Duration Therapies Spurs Innovation in Functional Cure Approaches
  • Growing Pipeline of Novel Nucleos(t)ide Analogs and Immunotherapies Drives R&D Investment
  • Increased Use of Combination Regimens Generates Demand for Optimized Treatment Protocols
  • Improved Access to Generic Medications Sustains Growth in Low- and Middle-Income Countries
  • Integration of Hepatitis B Care into Broader Public Health Programs Expands Treatment Reach
  • Rising Co-Infection Rates with HIV and Hepatitis D Spur Development of Broader-Spectrum Therapeutics
  • Digital Health Tools and Adherence Monitoring Platforms Drive Improved Patient Outcomes
  • Awareness Campaigns and Early Intervention Strategies Propel Patient Engagement and Treatment Initiation
  • Healthcare Infrastructure Improvements in Emerging Markets Strengthen Market Penetration
  • Persistent Stigma and Asymptomatic Nature of Disease Pose Challenges to Treatment Adoption
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Hepatitis B Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Hepatitis B Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Acute Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Acute Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Acute Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chronic Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Chronic Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Immune Modulator Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Immune Modulator Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Immune Modulator Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antiviral Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antiviral Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Antiviral Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Vaccines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Vaccines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Vaccines Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Alnylam Pharmaceuticals
  • Altimmune Inc.
  • Antios Therapeutics
  • Arbutus Biopharma Corporation
  • Assembly Biosciences
  • Bristol-Myers Squibb
  • Dicerna Pharmaceuticals
  • Enanta Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • LG Chem
  • MYR Pharmaceuticals GmbH
  • Replicor Inc.
  • Roche Holding AG
  • Sanofi
  • VBI Vaccines Inc.
  • Vir Biotechnology, Inc.

Table Information